Hodgkin's Lymphoma


FDA Approves Keytruda® for Adult and Pediatric Patients with Classical Hodgkin (March 29, 2017)

It was announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric... Continue Reading

2016-Year in Review: Advances in Management of Lymphomas (February 16, 2017)

Our understanding of lymphomas has allowed scientists to find new and unique ways of treating this blood cancer. Lymphoma treatments have expanded far beyond chemotherapy, though that type of treatment... Continue Reading

Progress Reported in New Treatments for People with Lymphoma (December 29, 2016)

Research and pharmaceutical executives unveil encouraging clinical trial data at the annual meeting of the American Society of Hematology. Twenty-two years ago, Dr. Gary Gordon, Ph.D., vice president of... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

Pass It On: July is National Leukemia and Lymphoma Awareness Month (September 1, 2016)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia... Continue Reading

Patients Rising: Voices of Value (September 1, 2016)

By Terry Wilcox When Jennifer Hinkel was diagnosed with Hodgkin’s lym­phoma in 1998 at the age of 17, her life as she knew it came to a standstill: from her daily routine to her long-term plans, her... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio... Continue Reading

Crafting a Better T Cell for Immunotherapy (February 25, 2016)

New technology, not yet tested in humans, aims to reduce patients’ waiting time, increase potency of T-cell therapy T-cell therapy, a form of immunotherapy that uses a patient’s own immune cells to... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma.... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (May 7, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with  Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

CancerConnect News: The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

CancerConnect News:The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

CancerConnect News– The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL)... Continue Reading

Radiation Therapy Improves 10-Year Survival for Patients With Early Hodgkin’s Lymphoma (October 30, 2014)

According to a large observational study based on the National Cancer Database (NCDB), adding consolidation radiation therapy to chemotherapy significantly improves 10-year survival in patients with stage... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS